CardioSignal presented data at ESC 2024 annual meeting on atrial fibrillation detection reliability among people suspected of various heart conditions
September 3, 2024
High detection accuracy for atrial fibrillation detection was established among a diverse group of patients suspected of arrhythmias, heart failure and coronary artery disease. Detection reliability is key when designing remote care initiatives in larger populations.
From 1524 patient recordings, atrial fibrillation was detected in 237 individuals with 97% accuracy using a smartphone as a measuring device. The smartphone was placed on the patient’s chest to measure heart kinetic motion with motion sensors. Two 60-second strips were analyzed from each recording.
CardioSignal’s CEO, co-founder, and cardiologist Juuso Blomster presented the results in the session: Transforming population health through mobile technology at the European Society of Cardiology (ESC) annual meeting that was being held in London on 30 August - 2 September.
“We need to prepare ourselves for the future where high-risk individuals are regularly screened in high volume for heart diseases such as atrial fibrillation or heart failure. This is a necessity if we are to address the growing burden of heart disease with the available healthcare resources”, Dr. Blomster says.
“We are not lacking the tools to do this. Rather, we lack the tools to do this in high volume while maintaining reliability. Reliability is a prerequisite for designing sustainable population health programs”, Blomster continues.
The CardioSignal application is currently available as a class IIa medical device for detecting atrial fibrillation.
CardioSignal is based on gyrocardiography, a proprietary method that measures heart motion and cardiac function. Motion changes are then analyzed for patterns characteristic of atrial fibrillation using a clinically validated algorithm.
Read more “Transforming population health through mobile technology”: https://esc365.escardio.org/ESC-Congress/sessions/11551
Study results in short:
Population: 1524 recordings from a total of 1192 patients, pooled from three different studies. The mean age of the patients was 64 years; mean BMI was 28.9
Results: The sensitivity to detect atrial fibrillation was 91.9% and specificity 98.7%. The accuracy for atrial fibrillation detection was 97.0%
The positive predictive value was 91% and the negative predictive value 98.3%
Method: The signals were collected by placing a smartphone on the chest of the patient when they lied down, and then analyzed with the CardioSignal solution.
Simultaneous 5-lead or 1-lead ECG data was collected for reference.
The ECG signals were analyzed for quality and rhythm diagnostics by 2 physicians who were blinded for the motion sensor atrial fibrillation detection result.
Further information:
CEO Juuso Blomster, juuso.blomster@cardiosignal.com
About CardioSignal
CardioSignal develops groundbreaking solutions for the detection of heart diseases using digital cardiac biomarkers. The CardioSignal technology utilizes the gyroscope and accelerometer motion sensors to non-invasively measure heart motion to determine cardiac health and function. The company has concluded successful clinical studies on detecting heart failure, with plans to launch in 2025.
Originally an academic spin-off, the company’s patented gyrocardiography technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product by Precordior Ltd, an ISO 13485 and ISO 27001 certified health technology company formed in 2017 with operations in Turku, Finland and Palo Alto, CA, USA.